Botulism descriptive drug profiles, therapeutic landscape Review Analysis 2019

Posted by Deeksha on September 30th, 2019

Market Research Hub (MRH) has recently uploaded a new study titled “Botulism-Pipeline Review, H2 2019” to its broad online storehouse. The global Botulism conveniently covers prime factors motivating development and steering industry trends and demand scenarios. Readers can easily quantify market opportunities with the availability of information such as market sizing and market forecasting, thereby being able to analyze the prevailing status across the global Botulism.

Get Sample Copy at

Botulism - Pipeline Review, H2 2019


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H2 2019, provides an overview of the Botulism (Infectious Disease) pipeline landscape.

Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Botulism - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Botulism (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Botulism (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 3 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Botulism (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Botulism (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Botulism (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Botulism (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Botulism (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Botulism (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Complete Report at

Table of Contents

List of Tables
List of Figures
Global Markets Direct Report Coverage
Botulism - Overview
Botulism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Botulism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Botulism - Companies Involved in Therapeutics Development
CytoDel Inc
Hawaii Biotech Inc
Ology Bioservices Inc
Botulism - Drug Profiles
bithionol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulinum vaccine [serogroups A, A1, B and B1] - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulism [serotype C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulism [serotypes A, B, E] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyto-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Botulinum Neurotoxin E for Botulism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTM-1632 - Drug Profile
Product Description
Mechanism Of Action

Continued……. @!


Like it? Share it!


About the Author

Joined: January 3rd, 2019
Articles Posted: 12,334

More by this author